Live Virus Vaccine Articles & Analysis
13 news found
Utilizing system biology approaches, adjuvant, mRNA, and vector-based technologies, Protheragen provides mRNA vaccine, DNA vaccine, live-attenuated vaccine, virus-like particle vaccine, protein subunit vaccine, and many other custom vaccines. Protheragen’s ...
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics is proud to announce the launch of its comprehensive portfolio of ELISA Based Assays for vaccine development and bioprocess applications. Vaccine development involves a variety of assays to support vaccine research and development, from early preclinical studies to final production, quality ...
Dr. Mark Prausnitz, co-founder and Chief Scientific Advisor of Micron Biomedical (“Micron”), today presented Micron’s technology for the simple administration of vaccines and therapeutics at a White House panel discussion titled Innovation in Vaccine Delivery chaired by Dr. Francis Collins. This summit outlined a path toward innovative, next-generation COVID-19 vaccines and ...
Bristol-Myers Squibb K.K. today announced that Japan’s Ministry of Health, Labour and Welfare has approved Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma, who have received at least three prior therapies, including an ...
Meissa’s intranasal recombinant live attenuated COVID-19 vaccine, MV-014-212, induced mucosal as well as systemic antibodies against SARS-CoV-2 and two variants of concern ? ...
· No vaccine is currently approved to protect against respiratory syncytial virus (RSV) · RSV is the leading cause of infant hospitalization in the United States and is considered the “missing” pediatric vaccine · Previous clinical data in seropositive adult and pediatric participants showed MV-012-968 was ...
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces it has achieved a key milestone in its project to develop needle-free thermostable unit solid-dose live vaccines with retained activity against Measles and Rubella. ...
Researchers arounad the world are putting tremendous effort toward developing vaccines and therapeutic drugs. Creative Biolabs has been dedicated to the discovery and development of different types of vaccines, including in silico vaccine, live attenuated and killed vaccine, recombinant subunit ...
Food and Drug Administration (FDA) for a Phase 1 clinical study of MV-014-212, the company’s intranasal live attenuated chimeric vaccine candidate against SARS-CoV-2, the coronavirus that causes COVID-19. ...
- The randomized, double-blind, placebo-controlled challenge study is designed to evaluate safety and prophylactic efficacy of MV-012-968 against symptomatic respiratory syncytial virus (RSV) - Previous clinical data shows MV-012-968 is well-tolerated, heavily attenuated, and induces an RSV-specific mucosal IgA response in healthy seropositive adults and pediatric participants ...
Food and Drug Administration (FDA) for the development of MV-014-210, a live attenuated vaccine (LAV) candidate to induce immunity and protect against SARS-CoV-2, the novel coronavirus that causes COVID-19. ...
Food and Drug Administration (FDA) has granted Fast Track Designation to MV-012-968, an investigational, live attenuated vaccine for protection against respiratory syncytial virus (RSV) infection. ...
T cell dependent secretory IgA (SIgA) generated in the Peyer’s patches (PPs) of the small intestine shapes a broadly diverse microbiota that is crucial for host physiology. The mutualistic co-evolution of host and microbes led to the relative tolerance of host’s immune system towards commensal microorganisms. The ATP-gated ionotropic P2X7 receptor limits T follicular helper (Tfh) ...